$AXON Insider Trading

FREE EMAIL WATCHDOG

Get free email notifications about insider trading in Sio Gene Therapies Inc..

Your email is safe with us.
The service is free and you can unsubscribe at any time.

General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview

Overview of all insider trading transactions in Sio Gene Therapies Inc.. Get notifications about new insider transactions in Sio Gene Therapies Inc. for free.

Page: 1

Date	Ticker	Company	Owner	Relationship	Transaction	Code	Cost ($)	Shares	Transaction Value ($)	Total Shares	% Holdings
Apr 19 2021	AXON	Sio Gene Therapies ...	Vuori Kristiina MD	Director	Option Exercise	A	2.47	42,000	103,740	42,000
Apr 19 2021	AXON	Sio Gene Therapies ...	Torti Frank	Director	Option Exercise	A	2.47	42,000	103,740	42,000
Apr 19 2021	AXON	Sio Gene Therapies ...	Sundaram Senthil Vel	Director	Option Exercise	A	2.47	42,000	103,740	42,000
Apr 19 2021	AXON	Sio Gene Therapies ...	Pande Atul	Director	Option Exercise	A	2.47	42,000	103,740	42,000
Apr 19 2021	AXON	Sio Gene Therapies ...	Modig Berndt	Director	Option Exercise	A	2.47	42,000	103,740	42,000
Apr 19 2021	AXON	Sio Gene Therapies ...	Nassif David W.	Chief Financial Off ...	Option Exercise	A	2.47	239,000	590,330	239,000
Apr 19 2021	AXON	Sio Gene Therapies ...	Nassif David W.	Chief Financial Off ...	Option Exercise	A	2.47	239,000	590,330	239,000
Apr 19 2021	AXON	Sio Gene Therapies ...	Corcoran Gavin	Chief R&D Officer	Option Exercise	A	2.47	244,300	603,421	244,300
Apr 19 2021	AXON	Sio Gene Therapies ...	Corcoran Gavin	Chief R&D Officer	Option Exercise	A	2.47	244,300	603,421	244,300
Apr 19 2021	AXON	Sio Gene Therapies ...	Cheruvu Pavan	Chief Executive Off ...	Option Exercise	A	2.47	682,100	1,684,787	682,100
Apr 19 2021	AXON	Sio Gene Therapies ...	Cheruvu Pavan	Chief Executive Off ...	Option Exercise	A	2.47	682,100	1,684,787	682,100
Mar 24 2021	AXON	Sio Gene Therapies ...	Cheruvu Pavan	Chief Executive Off ...	Buy	P	2.48	100,000	248,180	180,426	80.4 K to 180.4 K (+124.34 %)
Mar 22 2021	AXON	Sio Gene Therapies ...	Nassif David W.	Chief Financial Off ...	Option Exercise	D	0.00	15,060	0	0
Mar 22 2021	AXON	Sio Gene Therapies ...	Nassif David W.	Chief Financial Off ...	Grant	A	0.00	15,060	0	34,004	18.9 K to 34 K (+79.50 %)
Mar 19 2021	AXON	Sio Gene Therapies ...	Corcoran Gavin	Chief R&D Officer	Option Exercise	D	0.00	16,001	0	0
Mar 19 2021	AXON	Sio Gene Therapies ...	Corcoran Gavin	Chief R&D Officer	Grant	A	0.00	16,001	0	25,792	9.8 K to 25.8 K (+163.43 %)
Mar 19 2021	AXON	Sio Gene Therapies ...	Cheruvu Pavan	Chief Executive Off ...	Option Exercise	D	0.00	22,590	0	0
Mar 19 2021	AXON	Sio Gene Therapies ...	Cheruvu Pavan	Chief Executive Off ...	Grant	A	0.00	22,590	0	80,426	57.8 K to 80.4 K (+39.06 %)
Nov 25 2020	AXON	Sio Gene Therapies ...	Pande Atul	Director	Buy	P	2.34	10,000	23,399	33,370	23.4 K to 33.4 K (+42.79 %)
Oct 07 2020	AXON	Axovant Gene Thera ...	Vuori Kristiina MD	Director	Option Exercise	A	5.63	35,000	197,050	35,000
Oct 07 2020	AXON	Axovant Gene Thera ...	Vuori Kristiina MD	Director	Option Exercise	A	5.63	35,000	197,050	35,000
Jul 10 2020	AXON	Axovant Gene Thera ...	Pande Atul	Director	Buy	P	2.73	10,000	27,290	23,370	13.4 K to 23.4 K (+74.79 %)
Jul 10 2020	AXON	Axovant Gene Thera ...	Cheruvu Pavan	Principal Executive ...	Buy	P	2.74	37,500	102,638	57,836	20.3 K to 57.8 K (+184.40 %)
Jun 15 2020	AXON	Axovant Gene Thera ...	Nassif David W.	Principal Financial ...	Option Exercise	D	0.00	15,060	0	15,060
Jun 15 2020	AXON	Axovant Gene Thera ...	Nassif David W.	Principal Financial ...	Payment of Exercise	F	3.25	5,266	17,115	18,944	24.2 K to 18.9 K (-21.75 %)
Jun 15 2020	AXON	Axovant Gene Thera ...	Nassif David W.	Principal Financial ...	Grant	A	0.00	15,060	0	24,210	9.2 K to 24.2 K (+164.59 %)
Jun 15 2020	AXON	Axovant Gene Thera ...	Cheruvu Pavan	Principal Executive ...	Option Exercise	D	0.00	22,591	0	22,590
Jun 15 2020	AXON	Axovant Gene Thera ...	Cheruvu Pavan	Principal Executive ...	Payment of Exercise	F	3.09	9,755	30,143	20,336	30.1 K to 20.3 K (-32.42 %)
Jun 15 2020	AXON	Axovant Gene Thera ...	Cheruvu Pavan	Principal Executive ...	Grant	A	0.00	22,591	0	30,091	7.5 K to 30.1 K (+301.21 %)
Jun 15 2020	AXON	Axovant Gene Thera ...	Corcoran Gavin	Chief R&D Officer	Option Exercise	D	0.00	16,002	0	16,001
Jun 15 2020	AXON	Axovant Gene Thera ...	Corcoran Gavin	Chief R&D Officer	Payment of Exercise	F	3.46	6,211	21,490	9,791	16 K to 9.8 K (-38.81 %)
Jun 15 2020	AXON	Axovant Gene Thera ...	Corcoran Gavin	Chief R&D Officer	Grant	A	0.00	16,002	0	16,002	0 to 16 K
Apr 17 2020	AXON	Axovant Gene Thera ...	Modig Berndt	Director	Option Exercise	A	3.45	17,500	60,375	17,500
Apr 17 2020	AXON	Axovant Gene Thera ...	Pande Atul	Director	Option Exercise	A	3.45	17,500	60,375	17,500
Apr 17 2020	AXON	Axovant Gene Thera ...	Torti Frank	Director	Option Exercise	A	3.45	17,500	60,375	17,500
Apr 17 2020	AXON	Axovant Gene Thera ...	Sundaram Senthil Vel	Director	Option Exercise	A	3.45	17,500	60,375	17,500
Apr 17 2020	AXON	Axovant Gene Thera ...	Corcoran Gavin	EVP of R&D	Option Exercise	A	0.00	42,400	0	42,400
Apr 17 2020	AXON	Axovant Gene Thera ...	Corcoran Gavin	EVP of R&D	Option Exercise	A	3.45	63,700	219,765	63,700
Apr 17 2020	AXON	Axovant Gene Thera ...	Nassif David W.	Principal Financial ...	Option Exercise	A	0.00	52,600	0	52,600
Apr 17 2020	AXON	Axovant Gene Thera ...	Nassif David W.	Principal Financial ...	Option Exercise	A	3.45	78,900	272,205	78,900
Apr 17 2020	AXON	Axovant Gene Thera ...	Cheruvu Pavan	Principal Executive ...	Option Exercise	A	0.00	112,700	0	112,700
Apr 17 2020	AXON	Axovant Gene Thera ...	Cheruvu Pavan	Principal Executive ...	Option Exercise	A	3.45	169,100	583,395	169,100
Mar 18 2020	AXON	Axovant Gene Thera ...	Pande Atul	Director	Buy	P	1.78	10,000	17,844	13,370	3.4 K to 13.4 K (+296.74 %)
Feb 27 2020	AXON	Axovant Gene Thera ...	Roivant Sciences Ltd.	10% Owner	Buy	P	3.75	5,333,333	19,999,999	18,577,380	13.2 M to 18.6 M (+40.27 %)
Sep 24 2019	AXON	Axovant Gene Thera ...	Corcoran Gavin	EVP of R&D	Option Exercise	A	0.00	32,003	0	32,003
Sep 24 2019	AXON	Axovant Gene Thera ...	Nassif David W.	Principal Financial ...	Option Exercise	A	0.00	30,120	0	30,120
Sep 24 2019	AXON	Axovant Gene Thera ...	Cheruvu Pavan	Principal Executive ...	Option Exercise	A	0.00	45,181	0	45,181
Jul 02 2019	AXON	Axovant Gene Thera ...	Nassif David W.	Principal Financial ...	Option Exercise	A	6.42	75,000	481,500	75,000
Jul 02 2019	AXON	Axovant Gene Thera ...	Nassif David W.	Principal Financial ...	Option Exercise	A	6.42	150,000	963,000	150,000
Jul 01 2019	AXON	Axovant Gene Thera ...	Sundaram Senthil Vel	Director	Option Exercise	A	6.19	18,750	116,063	18,750
Jun 17 2019	AXON	Axovant Gene Thera ...	Cheruvu Pavan	Chief Executive Off ...	Buy	P	5.21	7,500	39,075	7,500	0 to 7.5 K
Jun 17 2019	AXON	Axovant Gene Thera ...	Pande Atul	Director	Buy	P	5.22	3,370	17,595	3,370	0 to 3.4 K
Apr 17 2019	AXON	Axovant Sciences L ...	Pande Atul	Director	Option Exercise	A	1.06	255,000	270,300	255,000
Apr 17 2019	AXON	Axovant Sciences L ...	Bickerstaff George	Director	Option Exercise	A	1.06	255,000	270,300	255,000
Apr 17 2019	AXON	Axovant Sciences L ...	POTTER MYRTLE S	Director	Option Exercise	A	1.06	255,000	270,300	255,000
Apr 17 2019	AXON	Axovant Sciences L ...	Torti Frank	Director	Option Exercise	A	1.06	255,000	270,300	255,000
Apr 17 2019	AXON	Axovant Sciences L ...	Corcoran Gavin	EVP of R&D	Option Exercise	A	1.06	200,000	212,000	200,000
Apr 17 2019	AXON	Axovant Sciences L ...	Corcoran Gavin	EVP of R&D	Option Exercise	A	1.06	767,000	813,020	767,000
Apr 17 2019	AXON	Axovant Sciences L ...	Modig Berndt	Director	Option Exercise	A	1.06	255,000	270,300	255,000
Apr 17 2019	AXON	Axovant Sciences L ...	Cheruvu Pavan	Chief Executive Off ...	Option Exercise	A	1.06	1,596,000	1,691,760	1,596,000
Apr 17 2019	AXON	Axovant Sciences L ...	Cheruvu Pavan	Chief Executive Off ...	Option Exercise	A	1.06	1,596,000	1,691,760	1,596,000
Apr 17 2019	AXON	Axovant Sciences L ...	Bazley Mathew C.	General Counsel	Option Exercise	A	1.06	250,000	265,000	250,000
Apr 17 2019	AXON	Axovant Sciences L ...	Bazley Mathew C.	General Counsel	Option Exercise	A	1.06	726,000	769,560	726,000
Apr 17 2019	AXON	Axovant Sciences L ...	JEFFS ROGER	Director	Option Exercise	A	1.06	255,000	270,300	255,000
Mar 19 2019	AXON	Axovant Sciences L ...	QVT Associates GP LLC	10% Owner	Buy	P	1.50	6,666,667	10,000,001	105,952,381	99.3 M to 106 M (+6.71 %)
Mar 19 2019	AXON	Axovant Sciences L ...	VIKING GLOBAL PERFORMANCE LLC	10% Owner	Buy	P	1.50	6,666,667	10,000,001	105,952,381	99.3 M to 106 M (+6.71 %)
Mar 19 2019	AXON	Axovant Sciences L ...	Machado Patrick	10% Owner	Buy	P	1.50	6,666,667	10,000,001	105,952,381	99.3 M to 106 M (+6.71 %)
Mar 19 2019	AXON	Axovant Sciences L ...	VIKING GLOBAL INVESTORS LP	10% Owner	Buy	P	1.50	6,666,667	10,000,001	105,952,381	99.3 M to 106 M (+6.71 %)
Mar 19 2019	AXON	Axovant Sciences L ...	SVF Investments (UK) Ltd	10% Owner	Buy	P	1.50	6,666,667	10,000,001	105,952,381	99.3 M to 106 M (+6.71 %)
Mar 19 2019	AXON	Axovant Sciences L ...	Lo Andrew	10% Owner	Buy	P	1.50	6,666,667	10,000,001	105,952,381	99.3 M to 106 M (+6.71 %)
Mar 19 2019	AXON	Axovant Sciences L ...	Roivant Sciences Ltd.	10% Owner	Buy	P	1.50	6,666,667	10,000,001	105,952,381	99.3 M to 106 M (+6.71 %)
Dec 20 2018	AXON	Axovant Sciences L ...	VIKING GLOBAL PERFORMANCE LLC	10% Owner	Buy	P	1.00	10,000,000	10,000,000	99,285,714	89.3 M to 99.3 M (+11.20 %)
Dec 20 2018	AXON	Axovant Sciences L ...	VIKING GLOBAL INVESTORS LP	10% Owner	Buy	P	1.00	10,000,000	10,000,000	99,285,714	89.3 M to 99.3 M (+11.20 %)
Dec 20 2018	AXON	Axovant Sciences L ...	Lo Andrew	10% Owner	Buy	P	1.00	10,000,000	10,000,000	99,285,714	89.3 M to 99.3 M (+11.20 %)
Dec 20 2018	AXON	Axovant Sciences L ...	Dexxon Holdings Ltd.	10% Owner	Buy	P	1.00	10,000,000	10,000,000	99,285,714	89.3 M to 99.3 M (+11.20 %)
Dec 20 2018	AXON	Axovant Sciences L ...	SVF Investments (UK) Ltd	10% Owner	Buy	P	1.00	10,000,000	10,000,000	99,285,714	89.3 M to 99.3 M (+11.20 %)
Dec 20 2018	AXON	Axovant Sciences L ...	QVT Associates GP LLC	10% Owner	Buy	P	1.00	10,000,000	10,000,000	99,285,714	89.3 M to 99.3 M (+11.20 %)
Dec 20 2018	AXON	Axovant Sciences L ...	Machado Patrick	10% Owner	Buy	P	1.00	10,000,000	10,000,000	99,285,714	89.3 M to 99.3 M (+11.20 %)
Dec 20 2018	AXON	Axovant Sciences L ...	Roivant Sciences Ltd.	10% Owner	Buy	P	1.00	10,000,000	10,000,000	99,285,714	89.3 M to 99.3 M (+11.20 %)
Oct 16 2018	AXON	Axovant Sciences L ...	POTTER MYRTLE S	Director	Option Exercise	A	2.37	150,000	355,500	150,000
Oct 16 2018	AXON	Axovant Sciences L ...	Torti Frank	Director	Option Exercise	A	2.37	150,000	355,500	150,000
Oct 03 2018	AXON	Axovant Sciences L ...	Bazley Mathew C.	General Counsel	Option Exercise	A	2.28	200,000	456,000	200,000
Oct 03 2018	AXON	Axovant Sciences L ...	Bazley Mathew C.	General Counsel	Option Exercise	A	2.28	250,000	570,000	250,000
Aug 17 2018	AXON	Axovant Sciences L ...	Lombardo Ilise	Chief Medical Offic ...	Option Exercise	A	2.02	100,000	202,000	100,000
Aug 13 2018	AXON	Axovant Sciences L ...	Bickerstaff George	Director	Buy	P	2.07	25,000	51,750	50,000	25 K to 50 K (+100.00 %)
Jul 20 2018	AXON	Axovant Sciences L ...	Corcoran Gavin	EVP of R&D	Option Exercise	A	2.46	200,000	492,000	200,000
Jul 20 2018	AXON	Axovant Sciences L ...	Corcoran Gavin	EVP of R&D	Option Exercise	A	2.46	250,000	615,000	250,000
Jun 07 2018	AXON	Axovant Sciences L ...	Lo Andrew	10% Owner	Buy	P	1.75	14,285,714	25,000,000	89,285,714	75 M to 89.3 M (+19.05 %)
Jun 07 2018	AXON	Axovant Sciences L ...	Dexxon Holdings Ltd.	10% Owner	Buy	P	1.75	14,285,714	25,000,000	89,285,714	75 M to 89.3 M (+19.05 %)
Jun 07 2018	AXON	Axovant Sciences L ...	QVT Associates GP LLC	10% Owner	Buy	P	1.75	14,285,714	25,000,000	89,285,714	75 M to 89.3 M (+19.05 %)
Jun 07 2018	AXON	Axovant Sciences L ...	SVF Investments (UK) Ltd	10% Owner	Buy	P	1.75	14,285,714	25,000,000	89,285,714	75 M to 89.3 M (+19.05 %)
Jun 07 2018	AXON	Axovant Sciences L ...	VIKING GLOBAL PERFORMANCE LLC	10% Owner	Buy	P	1.75	14,285,714	25,000,000	89,285,714	75 M to 89.3 M (+19.05 %)
Jun 07 2018	AXON	Axovant Sciences L ...	VIKING GLOBAL INVESTORS LP	10% Owner	Buy	P	1.75	14,285,714	25,000,000	89,285,714	75 M to 89.3 M (+19.05 %)
Jun 07 2018	AXON	Axovant Sciences L ...	Machado Patrick	10% Owner	Buy	P	1.75	14,285,714	25,000,000	89,285,714	75 M to 89.3 M (+19.05 %)
Jun 07 2018	AXON	Axovant Sciences L ...	Roivant Sciences Ltd.	10% Owner	Buy	P	1.75	14,285,714	25,000,000	89,285,714	75 M to 89.3 M (+19.05 %)
Mar 16 2018	AXON	Axovant Sciences L ...	Pande Atul	Director	Option Exercise	A	1.46	75,000	109,500	75,000
Mar 16 2018	AXON	Axovant Sciences L ...	Weinhoff Gregory M	Principal Financial ...	Option Exercise	A	1.46	450,000	657,000	450,000
Mar 16 2018	AXON	Axovant Sciences L ...	Weinhoff Gregory M	Principal Financial ...	Option Exercise	A	1.46	700,000	1,022,000	700,000
Mar 16 2018	AXON	Axovant Sciences L ...	Modig Berndt	Director	Option Exercise	A	1.46	75,000	109,500	75,000
Mar 16 2018	AXON	Axovant Sciences L ...	Altmeyer Mark	Pres (ASG) & Chief ...	Option Exercise	A	1.46	100,000	146,000	100,000
Mar 16 2018	AXON	Axovant Sciences L ...	Altmeyer Mark	Pres (ASG) & Chief ...	Option Exercise	A	1.46	340,000	496,400	340,000
Mar 16 2018	AXON	Axovant Sciences L ...	Mohr Stephen Frederick	General Counsel	Option Exercise	A	1.46	100,000	146,000	100,000
Mar 16 2018	AXON	Axovant Sciences L ...	Mohr Stephen Frederick	General Counsel	Option Exercise	A	1.46	250,000	365,000	250,000
Feb 15 2018	AXON	Axovant Sciences L ...	JEFFS ROGER	Director	Option Exercise	A	1.81	150,000	271,500	150,000
Feb 15 2018	AXON	Axovant Sciences L ...	Bickerstaff George	Director	Option Exercise	A	1.81	150,000	271,500	150,000
Feb 15 2018	AXON	Axovant Sciences L ...	Cheruvu Pavan	Chief Executive Off ...	Option Exercise	A	1.81	1,940,185	3,511,735	1,940,185
Jan 03 2018	AXON	Axovant Sciences L ...	Hung David	Principal Executive ...	Option Exercise	M	5.27	2,000,000	10,540,000	2,000,000
Jan 03 2018	AXON	Axovant Sciences L ...	Modig Berndt	Director	Option Exercise	M	0.90	77,914	70,123	7,086
Jan 03 2018	AXON	Axovant Sciences L ...	Modig Berndt	Director	Buy	M	0.90	77,914	70,123	77,914	0 to 77.9 K
Jul 19 2017	AXON	Axovant Sciences L ...	Machado Patrick	Director	Option Exercise	A	23.67	70,000	1,656,900	70,000
Jun 16 2017	AXON	Axovant Sciences L ...	Mohr Stephen Frederick	General Counsel	Option Exercise	A	20.72	187,400	3,882,928	187,400
May 16 2017	AXON	Axovant Sciences L ...	VERNON W ANTHONY	Director	Option Exercise	A	21.90	70,000	1,533,000	70,000
May 16 2017	AXON	Axovant Sciences L ...	FALBERG KATHRYN E	Director	Option Exercise	A	21.90	70,000	1,533,000	70,000
May 02 2017	AXON	Axovant Sciences L ...	OLANOFF LAWRENCE S	Director	Option Exercise	A	24.24	27,000	654,480	27,000
May 02 2017	AXON	Axovant Sciences L ...	Pisano Gary P.	Director	Option Exercise	A	24.24	27,000	654,480	27,000
May 02 2017	AXON	Axovant Sciences L ...	Modig Berndt	Director	Option Exercise	A	24.24	27,000	654,480	27,000
May 02 2017	AXON	Axovant Sciences L ...	Pande Atul	Director	Option Exercise	A	24.24	27,000	654,480	27,000
May 02 2017	AXON	Axovant Sciences L ...	Weinhoff Gregory M	Principal Financial ...	Option Exercise	A	24.24	175,000	4,242,000	175,000
May 02 2017	AXON	Axovant Sciences L ...	Altmeyer Mark	Pres (ASG) & Chief ...	Option Exercise	A	24.24	100,000	2,424,000	100,000
May 02 2017	AXON	Axovant Sciences L ...	Adasczik Michael	Principal Accountin ...	Option Exercise	A	24.24	12,500	303,000	12,500
May 02 2017	AXON	Axovant Sciences L ...	FRIEDHOFF LAWRENCE MD PHD	Chief Development O ...	Option Exercise	A	24.24	200,000	4,848,000	200,000
Apr 19 2017	AXON	Axovant Sciences L ...	VERNON W ANTHONY	Director	Buy	P	18.54	53,937	999,992	53,937	0 to 53.9 K
Apr 19 2017	AXON	Axovant Sciences L ...	FALBERG KATHRYN E	Director	Buy	P	18.54	53,937	999,992	53,937	0 to 53.9 K
Apr 19 2017	AXON	Axovant Sciences L ...	Hung David	Principal Executive ...	Buy	P	18.54	539,375	10,000,013	539,375	0 to 539.4 K
Apr 11 2017	AXON	Axovant Sciences L ...	McCourt Marion	Principal Operating ...	Option Exercise	A	15.13	465,000	7,035,450	465,000
Apr 11 2017	AXON	Axovant Sciences L ...	Hung David	Principal Executive ...	Option Exercise	A	15.13	2,000,000	30,260,000	2,000,000
Apr 11 2017	AXON	Axovant Sciences L ...	Hung David	Principal Executive ...	Option Exercise	A	15.13	2,000,000	30,260,000	2,000,000
Jun 17 2016	AXON	Axovant Sciences L ...	Pisano Gary P.	Director	Option Exercise	A	12.99	94,000	1,221,060	94,000
May 03 2016	AXON	Axovant Sciences L ...	Ramaswamy Vivek	Principal Executive ...	Option Exercise	A	13.00	357,000	4,641,000	357,000
May 03 2016	AXON	Axovant Sciences L ...	Cvijic Christine Mikail	Chief Admin Officer ...	Option Exercise	A	13.00	50,000	650,000	50,000
May 03 2016	AXON	Axovant Sciences L ...	OLANOFF LAWRENCE S	Director	Option Exercise	A	13.00	47,000	611,000	47,000
May 03 2016	AXON	Axovant Sciences L ...	Pande Atul	Director	Option Exercise	A	13.00	47,000	611,000	47,000
May 03 2016	AXON	Axovant Sciences L ...	FRIEDHOFF LAWRENCE MD PHD	Chief Development O ...	Option Exercise	A	13.00	175,000	2,275,000	175,000
May 03 2016	AXON	Axovant Sciences L ...	Adasczik Michael	Principal Accountin ...	Option Exercise	A	13.00	5,000	65,000	5,000
May 03 2016	AXON	Axovant Sciences L ...	Modig Berndt	Director	Option Exercise	A	13.00	47,000	611,000	47,000
May 03 2016	AXON	Axovant Sciences L ...	Romeo Marianne L.	Head,Global Trans & ...	Option Exercise	A	13.00	20,000	260,000	20,000
May 03 2016	AXON	Axovant Sciences L ...	Altmeyer Mark	Pres&Chief Commerci ...	Option Exercise	A	13.00	75,000	975,000	75,000
May 03 2016	AXON	Axovant Sciences L ...	Weinhoff Gregory M	Principal Financial ...	Option Exercise	A	13.00	200,000	2,600,000	200,000
Mar 14 2016	AXON	Axovant Sciences L ...	Altmeyer Mark	Pres&Chief Commerci ...	Buy	P	11.14	2,300	25,622	2,300	0 to 2.3 K
Sep 17 2015	AXON	Axovant Sciences L ...	Weinhoff Gregory M	Principal Financial ...	Option Exercise	A	16.49	454,096	7,488,043	454,096
Aug 18 2015	AXON	Axovant Sciences L ...	Adasczik Michael	Principal Accountin ...	Option Exercise	A	14.06	25,000	351,500	25,000
Jun 24 2015	AXON	Axovant Sciences L ...	OLANOFF LAWRENCE S	Director	Option Exercise	A	20.09	75,000	1,506,750	75,000

Page: 1